Baltimore-based Infinity Bio recently closed an $8 million Series A financing round, led by Illumina Ventures with participation from PTX Capital, Blackbird BioVentures, and the Propel Baltimore Fund. The funding marks a major milestone for the Johns Hopkins-founded company, which is creating technologies to map immune responses at scale through its proprietary MIPSA platform.
Infinity Bio operates as a service business: customers send in blood samples, and the company uses its proprietary technology to read out the antibody repertoire and return data. This data represents a type of omic information—unbiased, highly multiplexed, and rich with biological insight.
The company will use the funds to expand its commercial footprint, accelerate platform development, and launch new immune profiling services—including EnviroSIGHT™, a novel library targeting non-viral, non-human immune triggers, which launched earlier this month (July 2025). As part of its growth strategy, Infinity Bio has also acquired the assets of Serimmune, Inc., a complementary player in the antibody reactome space.
Infinity Bio was founded in 2023 by Joy Nassif, Chief Executive Officer, and Ben Larman, PhD, associate professor of pathology at Johns Hopkins University. The company’s core technology, MIPSA (Molecular Indexing of Proteins by Self Assembly), was developed in Larman’s lab with support from the National Institutes of Health. MIPSA enables high-throughput, DNA-barcoded profiling of antibody-antigen interactions, turning complex immunological data into scalable sequencing problems.
“We’re converting the antibody-antigen binding question into a DNA sequencing problem, which is easier to solve and more scalable,” says Larman, who also serves as Infinity Bio’s Chief Science Officer.
The company’s early success was fueled by Nassif’s operational leadership and deep experience in biotech service businesses. “Joy has been there since before the beginning,” Larman notes. “Her ability to build and scale operations was critical to getting us off the ground quickly.”
Infinity Bio’s story also reflects a broader trend in omics and precision medicine. The company draws inspiration from Olink, a Swedish proteomics firm that sold to Thermo Fisher for $3.1 billion in 2023. “We’re following a similar playbook,” says Larman. “But we’re doing it our way.”
Infinity Bio’s 9,000-square-foot lab in East Baltimore became operational by the end of 2023. Within its first year, the company achieved cash-flow break-even and served over 30 unique customers, including academic institutions, government agencies, and pharmaceutical companies.
One of its flagship projects was the TEDDY study (Environmental Determinants of Diabetes in the Young), where Infinity Bio screened over 10,000 samples to investigate infectious triggers of type 1 diabetes.
“True to our name, Infinity Bio is building a limitless capacity to generate high-quality antibody reactome data and deliver valuable biological insights,” said Larman.
Events like JHTV’s Innovation Summit helped Infinity Bio build strong early traction and visibility. Illumina Ventures, which had been tracking the company, saw an opportunity to back a platform with broad applications in diagnostics, therapeutics, and biomarker discovery.
Matt Hellauer, founder of PTX Capital and an early investor, adds: “Infinity Bio is opening up a black box that’s long existed in life sciences. Their platform is a new data layer for precision medicine.”
With strong ties to Johns Hopkins and support from local investors like PTX and TCP, the company is committed to growing in the city where it began.
“JHTV was instrumental in this process,” said Hellauer. “Their partnership helped us move fast and build credibility.”
Infinity Bio is poised to become a cornerstone of Baltimore’s biotech ecosystem. Its mission is clear: to make the immune system readable, actionable, and central to the next generation of medicine.
“We’re proud to be building this in Baltimore,” said Larman. “And we’re just getting started.”